Analystreport

BridgeBio Pharma (NASDAQ: BBIO) had its price target raised by analysts at Goldman Sachs Group Inc from $43.00 to $52.00.

BridgeBio Pharma, Inc.  (BBIO) 
Last bridgebio pharma, inc. earnings: 3/2 08:29 am Check Earnings Report